In this review, we focus on the genomic determinants of response to PI3K pathway inhibitors in cancer identified in preclinical models and clinical trials to date, and discuss the challenges for the development of molecular tools for the stratification of cancer patients. The gene discussed is PIK3CD; the disease is cancer.